DUBLIN, Oct. 30, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "China Independent Clinical Laboratory Industry Report, 2014-2017" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
The independent clinical laboratory industry starts relatively late in China, featuring a limited overall size but high-speed development. In 2013 the independent clinical laboratory market size there was around RMB3.5 billion, up as much as 70% yr-on-yr, yet only accounting for 2%-3% of the total revenue of medical diagnosis.
There are about 110 independent clinical laboratories in today's China, but most of them are small sized. KingMed Diagnostics, ADICON, DIAN Diagnostics and DAAN Gene as the strong performers thereof hold a combined market share of roughly 70%.
Because of a high requirement on the samples within a shorter time limit for place, the industry has a certain service radius. Therefore, a national layout is essential to business development and customer acquisition and chain-orientation the key development mode, for enterprises. KingMed Diagnostics, ADICON, DIAN Diagnostics and DAAN Gene have by far 19, 15, 14 and 8 independent medical laboratories across the country.
KingMed Diagnostics as the largest independent clinical laboratory enterprise in China enjoys a market share of approximately 40%, receiving recognition from both College of American Pathologists (CAP) and ISO15189. In the first half of 2014 it posted revenue of RMB846 million, up 37% yr-on-yr. Equipped with detection platforms for tumor diseases, genetic diseases, blood diseases, etc., KingMed Diagnostics will give top priority to tumor, reproduction and microbiological testing in the future.
ADICON is the first independent medical laboratory in domestic trans-regional chain operation, with a market share as high as 15%-18%. In recent years, many of its subsidiaries have successively won ISO15189 and CAP certificates
As an industry leader in the business model of "service + agent", DIAN Diagnostics gets involved in independent clinical laboratory, judicial expertise, diagnostic products agency and other areas. Currently, the company boasts an 18% market share in the Chinese independent clinical laboratory industry, capable of carrying out more than 1,000 medical diagnostic services.
Moreover, related enterprises abroad have also been well aware of the growth potential in China's independent clinical laboratory industry, and set foot in the Chinese market via cooperation with local companies.
In February 2012, Quest and KingMed Diagnostics entered into a strategic alliance and established the KingMed&Quest Diagnostics Alliance Laboratory. And the Tianbo Lab jointly set up bythe South Korea-based SK Group and Xi'an Tianlong Science & Technology Co.Ltd started business in July 2014.
Key Topics Covered:
1. Overview of Independent Clinical Laboratory
2. Overview of China Independent Clinical Laboratory Industry
3. Upstream and Downstream Markets of China Independent Clinical Laboratory Industry
4. Key Players
5. Forecast and Outlook
Companies Mentioned:
- ADICON
- ADINOVO
- Amoy Diagnostics
- CapitalBio
- DAAN Gene
- DIAN Diagnostic
- Deyi Diagnostics
- IPE-Bio
- Kindstar Global
- KingMed Diagnostics
- NYMPHAVN Biotechnology
- SurExam
For more information visit http://www.researchandmarkets.com/research/ggl942/china_independent
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
